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ProliferationA germline mutation (A339V) in thyroid transcription factor-1 (TITF1/NKX2.1) was shown to be associated with
multinodular goiter (MNG) and papillary thyroid carcinoma (PTC) pathogenesis. The overexpression of A339V
TTF1 signiﬁcantly promoted hormone-independent growth of the normal thyroid cells, representing a cause of
MNG and/or PTC. Nevertheless, the underlying mechanism still remains unclear. In this study, we used liquid
chromatography (LC)–tandem mass spectrometry (MS/MS)-based shotgun proteomics comparing the global
protein expression proﬁles of normal thyroid cells (PCCL3) that overexpressed the wild-type or A339V TTF1 to
identify key proteins implicated in this process. Proteomic pathway analysis revealed that the aberrant activation
of epidermal growth factor (EGF) signaling is signiﬁcantly associated with the overexpression of A339V TTF1 in
PCCL3, and clathrin heavy chain (Chc) is themost signiﬁcantly up-regulated protein of the pathway. Intriguingly,
dysregulated Chc expression facilitated a nuclear accumulation of pStat3, leading to an enhanced cell prolifera-
tion of the A339V clones. Down-regulation and abrogation of Chc-mediated cellular trafﬁcking, respectively, by
knocking-down Chc and ectopic expression of a dominant-negative (DN) form of Chc could signiﬁcantly reduce
the nuclear pStat3 and rescue the aberrant cell proliferation of the A339V clones. Subsequent expression analysis
further revealed that CHC and pSTAT3 are co-overexpressed in 66.7% (10/15) MNG. Taken together, our results
suggest that the A339V TTF1 mutant protein up-regulates the cellular expression of Chc, resulting in a constitu-
tive activation of Stat3 pathway, and prompting the aberrant growth of thyroid cells. This extensive growth signal
may promote the development of MNG.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Approximately 200 million people in the world suffer from some
form of thyroid disease. Thyroid nodules, thyroid lumps, or an enlarge-
ment of the thyroid gland known as goiter are themost common endo-
crine problem. It is estimated that 4–8% of adult women and 1–2% of
adult men have thyroid nodules that could be felt on physical examina-
tion, but closer to 30% ofwomen have nodules detectable by ultrasound.
Although the majority of thyroid nodules are benign (not cancerous),
about 10% of nodules do harbor a cancer. In addition, it is known that
about 6% of multinodular goiter (MNG) patients eventually develop
thyroid cancer [1–6].versity of Hong Kong, Pokfulam,
g, SAR, China. Tel.: +852 3917Papillary thyroid carcinoma (PTC) is the most common subtype of
thyroid malignancies, accounting for approximately 80% of all primary
thyroid cancers. Intriguingly, families with autosomal-dominant inher-
itance pattern for MNG, PTC, or both strongly suggest the presence of
common genetic determinants for MNG and PTC. Previously, our
group has identiﬁed a germline missense mutation (1016C N T) in
TITF1/NKX2.1 encoding amutant TTF1 protein (A339V),whichmay con-
tribute to predisposition forMNG and PTC, further highlighting a genet-
ic link between these two diseases [7]. The ectopic expression of the
A339V mutant protein in a normal rat thyroid PCCL3 cell line results
in a signiﬁcant up-regulation of cellular proliferation of these thyroid
cells and promotes their thyrotropin (thyroid-stimulating hormone,
TSH)-independent growth, which was in part attributed to activated
Stat3 survival signal in these cells [7]. Nevertheless, the underlying
mechanism for the A339V-associated proliferation remains largely
unclear.
In normal thyroid glands, a ﬁne regulation on thyrocyte growth and
differentiation is essential tomaintain tissue homeostasis; which occurs
through complex interactions between TSH and other growth factors
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found synthesized locally, and playing crucial roles in regulation of
thyroid proliferation and differentiation [9]. Aberrant EGF signaling
is commonly associated with the loss of thyroid speciﬁc functions,
goiter development, as well as enhanced PTC aggressiveness [9,10].
Similarly, as one of the downstream regulators of the EGF signaling
pathway, signal transducers and activators of transcription 3
(STAT3) is found to be highly expressed and activated in the tissue
specimens of thyroid cancers, including lymphatic metastasis of
PTC [11]. In particular, the activated form of the protein, pSTAT3, is
signiﬁcantly up-regulated in PTC with high metastatic potential
[11]. All these evidence suggest that an optimal level EGF-STAT3 sig-
naling must be achieved and cumulative alterations in this signaling
pathway may lead to the stepwise transition towards malignancy,
including gaining resistance to growth inhibition and ability to pro-
liferate independently on growth factors and to replicate inﬁnitely
[12].
Although we have previously identiﬁed a missense mutation in
TITF1/NKX2.1 (A339V) as a genetic cause for the predisposition of
MNG and PTC, to date, the molecular mechanism(s) underlying
this process is still elusive. In this study, we aimed to address this
question using a mass spectrometry-based quantitative proteomic
approach with our established in vitro cell line models. Our quantita-
tive proteomics study has identiﬁed proteins that are signiﬁcantly
dysregulated in thyroid cells that expressed A339V TTF1. In addition,
with pathway analysis, clathrin heavy chain (Chc) was deﬁned as the
most predominant EGF pathway component associated with the ab-
errant growth of these thyroid cells. Subsequent functional studies
further delineated the causal link between A339V mutation, the dys-
regulation of clathrin-mediated endocytosis (CME), and the aberrant
growth of thyroid cells. To further explore the clinical relevance of
Chc in MNG and/or PTC pathogenesis, we also examined the expres-
sion proﬁles of CHC and pSTAT3 in MNG and PTC samples from pa-
tients carrying wild-type TITF1. We showed that elevated Chc is
associated with the development of MNG, but not PTC. In summary,
with this integrated approach, we have demonstrated that aberrant
CME may represent a disease mechanism underlying the develop-
ment of benign thyroid lesions such as MNG.2. Materials and method
2.1. Patient samples
A total of 28 pairs of MNG/tumor and the adjacent non-tumor spec-
imens were collected for this study. All subjects enrolled in the study
were consecutive unrelated patients with a histological diagnosis of ei-
ther MNG/nodular hyperplasia (n = 15) or PTC (n = 13) who
underwent a complete thyroidectomy at our institution. For patients
with bilateral benign thyroid nodules or multifocal PTC, tumor tissue
was taken from the largest nodule while the non-tumor tissue was
taken either from the isthmus or the contralateral normal lobe. Fourteen
(50%) patients had a clinically palpable or signiﬁcant goiter at least
12 months before operation. All 13 patients with the diagnosis of PTC
belonged to the classic type (i.e. nohistological variants of PTC). Patients
with clinically occult microcarcinomawere not included.Most of the 28
patients were female (82.1%) and local ethnic Chinese (96.4%). The me-
dian ages of the MNG and PTC cohorts were 61 years (range: 30–
90 years) and 48 years (range: 8–82 years), respectively. All histological
diagnoses were made based on standardized criteria approved by the
World Health Organization [13]. None of the patients had past exposure
of the head and neck region to ionizing radiation. Ethical approval for
this study was obtained from the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West Cluster
(UW 06-369 T/1394). Informed consent was received from each
subject.2.2. Cell lines and stable transfectants
PCCL3 rat thyroid cell line was a gift from Professor Jean-Paul
Blondeau, France. Various stable transfectantswere generatedpreviously,
including PCCL3 stably transfected with the wild-type (pRC/CMV-WT)
(a gift fromDr Parviz Minoo, University of Southern California [14]), mu-
tant (pRC/CMV-A339V) TTF1, or empty vector pRC/CMV (Ctrl) (Promega,
Madison, WI) [7]. Brieﬂy, cells were maintained in H4 medium, which
consisted of Coon’s medium with F12 high zinc supplement (Sigma-
Aldrich, St Louis, MO) and 5% fetal bovine serum (Invitrogen, Carlsbad,
CA), 0.3 mg/mL L-glutamine, 1 mIU/mL thyrotropin (Sigma-Aldrich, St
Louis, MO), 10 μg/mL insulin, 5 μg/mL apo-transferrin, 10 nmol/L hydro-
cortisone, 250 ng/ml G418, and penicillin/streptomycin.
2.3. Liquid chromatography (LC)–tandem MS (MS/MS)
Cell lysates of PCCL3 stable transfectants (WT, A339V and Ctrl) were
puriﬁed, trypsin digested, and subjected to LC-MS/MS analysis as
described in the Supplementary method.
2.4. Cell proliferation assay
For eachwell in 96-well culture plates, 5 × 103 cellswere seeded and
cultured for 1 day to allow the cell attachment. The cell proliferation rate
wasmeasured using the colorimetric Cell Proliferation ELISA kit (Roche,
Indianapolis, IN) in the presence or absence of Stat3 inhibitor (100 μM).
In brief, a 1 μM solution of BrdUwas added to the cell culture 4 h before
the assay. After the incubation hours, cells were ﬁxed, blocked, and in-
cubated with anti-BrdU antibody according to the manufacturer’s
protocol.
For the overexpression/knockdown experiments, cells were ﬁrst
transfectedwithpEGFP-C1-Chc(1-479), pCMV-EGFP (a gift fromProfes-
sor Steven J. Royle, University of Liverpool, UK), non-silencing (NS)
siRNA (5′-UUCUCCGAACGUGUCACGUUU-3′), or si-Chc (5′-AGGACCUU
CAGAAGGGCGAUU-3′) with/without GFP-CHC17KDP (Addgene, Plas-
mid #59799). Cell proliferation analyses were performed at 48 h after
transfection. Three independent experiments were performed with
the selected stable transfected clones, and each experiment was per-
formed in triplicates.
2.5. Immunoblotting
To examine the expression of the target proteins in the patient tis-
sues and stable transfectants, tissues or cells were lysed. Cell lysates
containing 10–30 μg of total or fractionated (cytoplasmic or nuclear
faction) protein were separated on 10 % sodium dodecyl sulfate–
polyacrylamide gels and blotted onto nitrocellulose membranes. The
membranes were then incubated with primary antibodies listed in
Supplementary Table 1. The same membranes were probed with anti-
β-actin, anti-β-tubulin, or anti-histone antibody to ensure equal loading
of cell protein per lane. All blots were incubated with secondary horse-
radish peroxidase-conjugated antibody. Antibody-bound proteins were
visualized using a chemiluminescence system (Amersham Biosciences,
Piscataway, NJ).
For examining Egfr recycling, cells were cultured in serum free
Coon’s medium for 6 h before addition of EGF. Cells were harvested at
0, 30, and 90 min after addition of EGF (100 ng/ml) with or without
pretreatment with choroquine (100 μM for 3 hrs at 37 °C).
2.6. Immunocytochemistry
Stable transfectants (3 × 104 cells per well in 24-well plate) were
seeded on poly-D-lysine coated coverslips. Some of the wells were sub-
jected to transient transfection with either pEGFP-C1-Chc(1-479) or
pCMV-EGFP for 24 h prior to harvesting and ﬁxation. After 4 % parafor-
maldehyde ﬁxation, cells were blocked with 1% bovine Serum albumin
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polyclonal antibody against Chc or pStat3 at 4 °C. The cells were subse-
quently washed with PBS and further incubated with Alexoﬂuor sec-
ondary antibodies for 2 h at room temperature in dark. Vectashield®
with DAPI (Vector Laboratories, Inc., Burlingame, CA) was used as the
mounting medium. Signals were detected, and images were captured
with a Nikon Eclipse 80i upright Fluorescence microscope (Nikon,
Melville, NY).2.7. Luciferase reporter assay
Cos-7 cells (3 × 104 per well in 24-well plate) were transfected with
250 ng of a reporter plasmid that encoded ﬁreﬂy luciferase under the
control of the Chc promoter of different length, 50 ng of a reporter plas-
mid that encoded Renilla luciferase under the control of the SV40 pro-
moter (pRL-SV40), and 400 ng of the WT (pRc/CMV-WT) or mutant
(pRc/CMV-A339V) TTF1 expression plasmid or empty vector (pRc/
CMV) to compare the ability of WT and A339V to transactivate the Chc
promoter. Luciferase reporter assays were carried out using the Dual-
Luciferase Reporter Assay System (Promega) according to themanufac-
turer’s protocol. Twenty-four hours after transient transfection, cells
were washed once with phosphate-buffered saline and harvested
in 50 μL passive lysis buffer (Promega). Luminescence measurements
were made on 10 μL of each sample lysate with a Microplate
Luminometer LB96V (Berthold Technology, Bad Wildbad, Germany).
Fireﬂy luciferase activitywas normalized against Renilla luciferase activ-
ity to correct for variations in transfection efﬁciency.2.8. Electrophoretic mobility shift assay (EMSA)
The interaction of WT and A339V with the Chc promoter was
assessed using EMSA. Chc promoter DNA (1kp) was ampliﬁed
with TaqGold polymerase using primer pairs Rat CHCpromo-F5 (5′-
CTGCGGTACCCGTCAGAAGGGGCGTGCGTCA-3′) and Rat CHCpromo-R
(5′-CTGCACGCGTGGCCGCTAGCTTCCTTCCCA-3′) and annealing tem-
peratures of 56 °C. EMSAs were performed using the Electrophoretic
Mobility Shift Assay kit (Invitrogen) according to the basic protocol sup-
plied by the manufacturer. In brief, protein–DNA samples were then in-
cubated on ice for 30 min in 1 × binding buffer (700 mM KCl, 2.5 mM
DTT, 2 mM EDTA, 25 mM Tris-HCl, 10 mM MgCl2, and 2% glycerol).
The samples were run on a 5% TBE nondenaturing polyacrylamide gel
in 0.5× TBE buffer before being stained with SYBR® Green for 30 min
to stain for DNA and imaged on Syngene G:Box followed by 3 h of stain-
ingwith SYPRO® Ruby followed by destaining and imaging on Syngene
G:Box to monitor for the colocalization of DNA and protein in shifted
bands.2.9. Statistical analysis
Fisher’s exact testwas used for comparison of dichotomous variables
and the Mann–Whitney U-test was used for continuous variables be-
tween groups. Continuous clinical variables were expressed as median
(range). Statistical analysis was performed using the SPSS statistics soft-
ware package (SPSS, Chicago, IL). Statistical comparisons for the cell
proliferation rates among the three groups of stable cell lines were
done by one-way ANOVA followed by Tukey post-test. All experiments
were performedwith at least three samples per group, and results were
derived from at least three independent experiments. Experimental
datawere expressed asmean values±SEM. Statistical analysiswasper-
formed using the GraphPad Prism 5 (GraphPad Software, San Diego,
CA). Unless otherwise speciﬁed, comparison between any 2-treatment
groups was analyzed by Student t-test. A p-value less than 0.05 was
interpreted to represent a statistically signiﬁcant difference.3. Results
3.1. Proteomic pathway analysis reveals up-regulation of EGF pathway in
PCCL3 that overexpressed with A339V TTF1
To elucidate the potential molecular effects upon the expression of
mutant A339V TTF1 in PCCL3, LC-MS/MS-based shotgun proteomics
were performed to compare the global protein expression proﬁles of
rat normal thyroid cell lines (PCCL3) that overexpressed the WT or
A339V TTF1 or that contained an empty vector as a control (Ctrl).
After excluding single spectrum-matched proteins, comparative proteo-
mic analysis revealed that twenty-three and thirty-seven proteins are
differentially expressed in PCCL3 that overexpressed A339V TTF1,
when compared to that of WT and the control (Ctrl) clone. A label-
free quantitative approach was employed, and the relative abundance
was based on the sum of total fragment ion intensities of peptides
matched inWT,A339V, and Ctrl clones. The identities and relative abun-
dance of the differentially expressed proteins are summarized in Table 1
and Supplementary Table 2.
A full list of proteins identiﬁed from each sample alongwith their ac-
cession numbers and abundances was uploaded to ExPlain™. Proteins
were automatically converted to corresponding gene identiﬁcations
upon data uploading, which were then mapped to upstream key
nodes in cellular pathways. To combine the results for the comparisons,
a score (S) was calculated for each pathway by combining both the in-
formation of up- and down-regulated pathways. The identiﬁed path-
ways were binned according to their scores (S) and plotted as a bar
chart (Fig. 1A, sample). The up-regulated pathways were indicated by
positive score, while the down-regulated pathways were indicated by
negative scores. As shown in Fig. 1A, the histogramwas sigmoid and al-
most symmetric, suggesting that the distribution of these Scores is nor-
mal. To determine if the calculated score could be resulted by chance,
the threshold value of score (S0) was accessed by randomizing the
ranks of the pathways and calculated the score with the same formulae
as the real data (Fig. 1A, random). Again, the S0 were found distributed
normally and symmetrically, and itwas highly comparable to that of the
samples. Then we used S0 as a reference to identify the pathways that
were signiﬁcantly different among samples. Those pathways with a
score larger than the positive threshold valuewere considered as signif-
icantly up-regulated; pathways with a score smaller than the negative
threshold value were considered as signiﬁcantly down-regulated.
The p-value of each pathway could be deduced as follows: p-value =
10−(S − S0). Reasonably, a low p-value can be obtained by two replicates
for each sample using this cross pairwise comparisonsmethod (Supple-
mentary method).
Comparisons of two pathway analyses were performed: A339V vs
WT TTF1 PCCL3 transfectants and WT vs PCCL3 transfected with
empty vector (Ctrl). Two signiﬁcantly up-regulated pathways and 5 sig-
niﬁcantly down-regulated pathwayswere consistently detected in both
A339V clones C1 and C2. When we compare A339V C1 with WT, EGF
pathway came up with the highest score (11.36) being rank 1 in 4 out
of 4 comparisons,with a p-value of 1.35× 10−7. The experimentwas re-
peated with another individual clone of mutant (A339V C2) that gave
similar results, with a score of 10.76 and a p-value of 4.23 × 10−6
(Fig. 1A). Intriguingly, whenwe performed an additional control exper-
iment by comparing the pathway results of the Ctrl and that of theWT-
TTF1-transfected PCCL3, we found that EGF pathway is slightly down-
regulated in cells overexpressing WT-TTF1 with a score and a p-value
of−6.16 and 2.84 × 10−2, respectively (Fig. 1B). These data support
the notion that TTF1-mediated down-regulation of EGF pathway is
essential for thyroid cell differentiation, and this process may be
interrupted in patients carrying mutant TTF1.
With our MS data, multiple proteins associated with the EGF path-
waywere identiﬁed as differentially expressed in A339V andWTclones,
including clathrin heavy chain (Chc), synthetic high osmolarity-
sensitive-1 (Flna), Ras related C3 botulinum toxin substrate-1 (Rac1),
Table 1
Complete list of proteins that are differentially expressed in A339V and TTF1 overexpressing cells.
Accession Gene Description Coverage No.
peptide
Score A339V WT log2
[A339V/WT]
IPI00214582 LOC497813 40S ribosomal protein S7 21.65 3 14.06 251481 2951 6.41
IPI00958405 LOC100362830 Ribosomal protein S7-like 24.64 4 23.09 251481 2951 6.41
IPI00203358 Ppp1cc Isoform Gamma-1 of serine/threonine-protein phosphatase PP1-gamma
catalytic subunit
8.98 2 14.67 1259263 233714 2.43
IPI00203390 Ppp1cb Serine/threonine-protein phosphatase PP1-beta catalytic subunit 8.87 2 14.67 1259263 233714 2.43
IPI00208265 Ppp1ca Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 8.79 2 14.67 1259263 233714 2.43
IPI00231715 Ppp1cc Isoform Gamma-2 of serine/threonine-protein phosphatase PP1-gamma
catalytic subunit
8.61 2 14.67 1259263 233714 2.43
IPI00368473 Numa1 Nuclear mitotic apparatus protein 1 9.70 17 24.86 587092 165278 1.83
IPI00766825 Numa1 Nuclear mitotic apparatus protein 1 isoform 2 9.78 17 24.86 587092 165278 1.83
IPI00208917 Aldh7a1 Alpha-aminoadipic semialdehyde dehydrogenase 18.74 8 18.82 538662 173685 1.63
IPI00212697 Napsa Napsin A aspartic peptidase 6.90 3 15.98 603828 221076 1.45
IPI00212989 Olah S-acyl fatty acid synthase thioesterase, medium chain 11.41 2 6.73 307333 120351 1.35
IPI00364865 Tex10 Uncharacterized protein 4.20 3 6.37 147813 58964 1.33
IPI00189074 Pabpc1 Polyadenylate-binding protein 1 17.92 10 34.92 289658 118827 1.29
IPI00213463 Actn4 Alpha-actinin-4 31.39 23 74.97 1894923 868125 1.13
IPI00231506 Pgam2 Phosphoglycerate mutase 2 18.18 6 25.36 392540 183683 1.10
IPI00209082 Actn1 Alpha-actinin-1 28.03 19 73.44 2075142 980540 1.08
IPI00454431 Actn1 Brain-speciﬁc alpha-actinin 1 isoform 29.10 20 77.16 2075142 980540 1.08
IPI00949794 Actn1 Actn1 protein 28.18 19 73.44 2075142 980540 1.08
IPI00951030 Actn1 100 kDa protein 28.84 19 73.44 2075142 980540 1.08
IPI00193983 Cltc Clathrin heavy chain 1 19.76 24 80.15 1359887 657720 1.05
IPI00776558 Cltc Uncharacterized protein 19.71 24 80.15 1359887 657720 1.05
IPI00193279 Oat Ornithine aminotransferase, mitochondrial 31.66 10 61.58 345820 697622 −1.01
IPI00363236 Lars Leucyl-tRNA synthetase 7.04 6 15.27 250663 534731 −1.09
IPI00454293 Serinc1 LRRGT00191 2.90 4 13.54 208685 449773 −1.11
IPI00776730 LOC316460 Uncharacterized protein 5.98 15 25.86 2409500 5234776 −1.12
IPI00957757 LOC316460 Uncharacterized protein 5.80 14 23.35 2409500 5234776 −1.12
IPI00209690 Ephx1 Epoxide hydrolase 1 15.82 5 16.17 270774 676355 −1.32
IPI00215277 Pdzd2 PDZ domain-containing protein 2 4.81 9 22.75 1167793 3058996 −1.39
IPI00779574 Pdzd2 280 kDa protein 5.04 9 22.75 1167793 3058996 −1.39
IPI00768895 LOC690147 Epoxide hydrolase 1 19.94 4 12.23 156468 461532 −1.56
IPI00951179 LOC690147 51 kDa protein 14.03 4 12.23 156468 461532 −1.56
IPI00339124 Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1 19.41 5 23.66 672203 2057873 −1.61
IPI00421500 Hnrnpa1 Heterogeneous nuclear ribonucleoprotein A1 21.88 6 36.96 144327 456800 −1.66
IPI00780243 Hnrnpa1 Uncharacterized protein 13.43 4 27.37 144327 456800 −1.66
IPI00781944 Hnrnpa1 Uncharacterized protein 18.77 6 35.28 144327 456800 −1.66
IPI00231502 Ap2b1 Isoform 2 of AP-2 complex subunit beta 8.73 6 17.49 60055 473556 −2.98
IPI00389753 Ap2b1 Isoform 1 of AP-2 complex subunit beta 8.86 6 17.49 60055 473556 −2.98
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which, Chc was the most signiﬁcantly up-regulated candidate in both
A339V clones (A3399VC1: 2.38 folds; A339V C2: 3.07 folds)when com-
pared to PCCL3 that overexpressed with WT-TTF1.
3.2. Dysregulation of Chc and EGF receptor recycling in A339V PCCL3 cells
To validate the proteomics data, the expression of Chc protein in
A339V PCCL3 was examined using immunoblotting (Fig. 2A) and im-
munocytochemistry (Fig. 2B), in which two independent clones of
A339V, WT and Ctrl, were included. In concordant with our proteomics
data, expression levels of Chc in A339V clones were higher than that of
the Ctrl and WT clones, where Chc is mainly expressed in cytoplasm of
these cells. It has been shown that clathrin-dependent endocytosis
(CME) prolongs the duration of EGF signaling by sustaining Egfr
recycling [15]. Therefore, we also monitored the Egfr degradation and
recycling processes in WT-TTF1 and A339V-transfected PCCL3. As illus-
trated in Fig. 2C, 90 min after addition of EGF, Egfr was completely de-
graded in WT-TTF1-transfected PCCL3. In A339V PCCL3, the recycling
process happened much faster, and a complete degradation was
observed in 30 min, wherein we could detect Egfr expression again at
90 min. More importantly, when chloroquine was added into the
cultures to inhibit CME by affecting the function of clathrin and
clathrin-coated vesicles, the Egfr degradation was abolished is in both
A339V andWT-TTF1-transfected PCCL3, suggesting that the Egfr degra-
dation/recycling is clathrin dependent. Taken together, the ectopicoverexpression of A339V TTF1 would prolong EGF signaling by sustain-
ing the CME-dependent Egfr recycling.
3.3. Activation of Stat3 pathway promotes cell proliferation of A339V TTF1
PCCL3 cells
Depending on different cellular contexts, EGF pathway typically pro-
motes cell survival, growth, and tumorigenesis, through the activation
of AKT/PKB or/and Src/STAT3 downstream signaling. The constitutive
activation of Stat3 (Ser727) has been previously identiﬁed as the
predominant survival signaling pathway for the A339V-associated pro-
liferation [7]. In addition, clathrin also represents a key trafﬁcking com-
ponent for cytoplasmic transport of pStat3 from cell membrane to peri-
nuclear region [16,17]. Therefore, it is conceivable that up-regulated
levels of Chc may also promote the nuclear accumulation of pStat3
(Ser727) in A339V clones. Immunoblotting results with lysates of vari-
ous stable clones indicated that A339V clones with higher Chc expres-
sion have signiﬁcantly higher amount of total pStat3 (Fig. 3A) and
nuclear pStat3 (Fig. 3B), while the Stat3 levels remained similar to
those of WT and Ctrl clones (Fig. 3A). Consistent results were observed
from immunoﬂuorescence images (Fig. 3C) inwhich pStat3were highly
expressed in nuclei of these A339V-transfected PCCL3 cells. In contrast,
both Ctrl and WT clones showed less Chc (Fig. 3C) and pStat3 staining
(Fig. 3C). Furthermore, the nuclear accumulation of pStat3 likely con-
tributes to the A339V-associated proliferation of PCCL3 cells because
the proliferation rate of these cells was signiﬁcantly reduced when a
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Significantly down-regulated pathways Score (S) p-value
IFNalpha,IFNbeta,IFNgamma -6.03 3.80E-02
EGF pathway -6.16 2.84E-02
insulin pathway -6.17 2.79E-02
RhoA pathway -6.20 2.60E-02
PRL pathway -6.43 1.53E-02
tuberin pathway -7.44 1.48E-03
IFN pathway -8.27 2.20E-04
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served in A339V clones, but not in PCCL3 cells transfected with empty
vector (Ctrl) or wild-type TTF1 (WT) (Fig. 3D).
3.4. Chc mediates cellular trafﬁcking of pStat3 in A339V clones
Although the cellular trafﬁcking roles of Chc are well established,
Chc has recently been shown to promotemitosis by directlymodulating
the mitotic spindle. To speciﬁcally address whether Chc contributes to
the A339V-associated proliferation through its cellular trafﬁcking and/
or the mitotic function, the endogenous function of Chc was abolished
by two approaches: (1) down-regulation of Chc with siRNA or (2) over-
expression of a construct encoding only the N-terminal domain (amino
acid 1-479) of Chc, which encodes a dominant-negative (DN) form of
Chc to speciﬁcally prohibit its cellular trafﬁcking function [18]. Immuno-
blotting results indicated that knockdown of Chc by siRNA profoundly
reduced nuclear pStat3 and total Stat3, which are accompanied by an
accumulation of cytoplasmic pStat3 (Fig. 4A). Importantly, the cell pro-
liferation rates of the A339V C1 and C2 clones were signiﬁcantly
dropped at 48 h post-transfection, and the inhibitory effect of si-Chc
could be recused by the overexpression of wild-type Chc (Fig. 4B).
These data indicated that elevated Chc directly contributes to the in-
creased cellular proliferation rates observed in A339V clones. Similarly,
the overexpression of theDNChc also reduced nuclear pStat3, accompa-
nied by an accumulation of cytoplasmic pStat3. However, in this case,
the total Stat3 was not affected (Fig. 4C). In regards to the cell prolifer-
ation, the ectopic expression of DN Chc signiﬁcantly decreased cell pro-
liferation rates of A339V clones and that reached back to the levelsimilar to those of both the Ctrl andWT clones (Fig. 4D). These indicated
that the elevated cellular proliferation rates observed in A339V clones
are attributed to the subcellular trafﬁcking function of Chc. Taken to-
gether, the elevated expression of Chc in A339V clones could favor nu-
clear localization of pStat3 protein and hence activate its downstream
survival signaling, leading to increased cell proliferation rates.
3.5. A339V TTF1 aberrantly transactivates Chc in PCCL3
We next elucidated how A339V TTF1 induces Chc expression. It is
noteworthy that A339V mutation is not residing in any of known func-
tional domains for DNA binding or transactivation activity of TTF1, but
A339Vmutant still exhibits defect on binding onto its consensus regula-
tory sequence to activate its target gene expression. Therefore, we spec-
ulated that A339V TTF1 still retains its transactivation activity, while the
A339Vmutation on TTF1may lead to the loss of promoter-speciﬁc DNA
binding of TTF1. It could result in a random binding to the Chc promoter
and a dysregulated transactivation of Chc. To test our hypothesis, we
ﬁrst evaluate the mRNA level of Chc in the stable clones by real-time
quantitative PCR.While those of the Ctrl andWT clones remained at rel-
atively similar levels, the average ChcmRNA level in A339V clones was
found signiﬁcantly higher than that of the Ctrl and WT clones by ap-
proximately 2 folds (Fig. 5A), suggesting enhanced Chc expressions ob-
served in A339V clones were due to alterations at transcriptional level.
We then used a two-tier approach to locate the binding site: we ﬁrst
used rVISTA to search for the putative TTF1 binding motif. rVISTA com-
bines searching the major transcription binding site database
TRANSFAC Professional from Biobase with a comparative sequence
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Fig. 2. Elevated expression of Chc and Egfr recycling in A339V clones. (A) Immunoblotting was performed for evaluating the relative protein abundance of Chc in the PCCL3 transfectants
(PCCL3 transfected with pRC/CMV (Ctrl), pRC/CMV-TTF1 (WT),and pRC/CMV-A339V TTF1 (A339V)). Actin was used as the loading control. The intensities of the bands were quantiﬁed
and the normalized values are shown in the bar chart. (B) Immunocytochemistry analysiswas performed to examine the cellular localization of Chc in PCCL3 transfectants. Representative
images are shown (magniﬁcation, ×400). Note that elevated Chc expressionwas observed in clones overexpressingmutant TTF1 (A339V)when compared to the clones expressing vector
(Ctrl) or wild-type (WT) TTF1. (C) Cells were treated with choroquine (100 μM for 3 hrs at 37 °C) and EGF (100 ng/ml) as indicated. Western blot analysis was performed to detect Egfr
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“TTF1 binding sites” in the Chcminimal promoter. Given that previous
functional studies from us and the others showed that CAAG … CTTG
is the TTF1 core consequence sequence identiﬁed in the thyroid (Tgpro-
moter) [7] and lung (SFTPA1 promoter) [19] cells, we limited our search
with this sequence and no CAAG… CTTGwas found in the Chcminimal
promoter. To further demonstrate that the dysregulated Chc expression
is due to the aberrant transactivation by mutant TTF1, luciferase report
assays were performed. We transfected Cos-7 with a plasmid encoding
ﬁreﬂy luciferase under the control of Chc promoter containing either
1 kb or 2 kb proximal promoter sequence (pGL3-Chc), expression
vectors for WT (pRc/CMV-WT) or A339V TTF1 (pRC/CMV-A339V), or
the control empty vector (pRc/CMV-WT), and with a plasmid encoding
Renilla luciferase (pRL-SV40). The extent to which TTF1 transactivates
the Chc promoter was assessed by normalizing ﬁreﬂy luciferase activity
to Renilla luciferase activity. The basal promoter activities of the 1 kb and
2 kb Chc promoters are comparable. The overexpression ofWT-TTF1 did
not further increase the promoter activity of the Chc, and the relativeluciferase activities were found similar in both cells transfected with
WT TTF1 and control empty vector. In contrast, the overexpression of
A339V TTF1 resulted in signiﬁcant increases in the promoter activities
of both 1 kb and 2 kb Chc promoters by 2.01 ± 0.76 and 2.29 ± 0.12
folds, respectively (Fig. 5B). In the subsequent gel mobility shift assay,
distinct bands were observed with the WT and A339V PCCL3 nuclear
proteins (Fig. 5C, nuclear stain). These bands were speciﬁc because
there was a dose-dependent increase in the amount of proteins that
bind on the proximal 1 kb Chc promoter (Fig. 5C, protein stain). Togeth-
erwith the data from the luciferase reporter assays, themutant TTF1 ab-
errantly transactivates Chc gene and the putative binding site for A339V
TTF1 is likely located within the proximal 1 kb of the Chc promoter.
3.6. Elevated Chc and pSTAT3 expression in MNG
Our previous study showed that patients harboring A339V TITF1
developed both MNG and PTC and it is not clear whether Chc itself is
implicated in the development of MNG, PTC, or both. To assess the
A
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amined CHC expression levels in 15 resected MNG and 13 primary
PTC tumors from patients who carry wild-type TITF1 using Western
blotting. Increased CHC expression was detected in 11 of the 15 MNG
samples (73.3%, marked by “*”), and no CHC expression was detectedin the 13 PTC tumor samples (0.0%) (p b 0.001, Fisher’s exact test) com-
pared with matched adjacent thyroid/non-tumor tissue samples
(Fig. 6). Intriguingly, among these 11 MNG samples with elevated CHC
expression, 10 of them also exhibited increased pSTAT3 expression.
These data have highlighted the potential link between the elevated
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and additional hits or factors are likely required for the development
of PTC. Table 2 compares the characteristics between patients withMNG and with PTC. Age at operation, clinical presentation, history of
thyroid surgery or thyrotoxicosis, and size of excised thyroid tissues
between the two groups were comparable.
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In thyroid cells with an ectopic expression of A339V TTF1, Stat3 has
been shown to be aberrantly phosphorylated and is believed to be the
major survival signal in these cells [7]. In this study,we further delineat-
ed a possible role of EGF/Chc/STAT3 signaling inMNG development.We
demonstrated that A339Vmutation substantially perturbs gene-speciﬁc
transactivation activity of TTF1 and results in an aberrant expression of
Chc. Chc is a major component of CMEwhichmediates cellular material
uptake and trafﬁcking. Chc is ubiquitously expressed in normal tissues,
while its pathological role in human diseases is still not clear. With thy-
roid cells overexpressing A339V TTF1, we showed that elevated Chc
promotes Egfr recycling as well as activation of Stat3 pathway, one of
the major EGF downstream pathways, which may cause a prolonged
EGF signaling and enhance EGF-dependent biological responses [15].As matter of fact that, the Stat3 pathway is consistently activated in
A339V clones and MNG samples, closely associated with Chc expres-
sion. More importantly, our data also indicated that elevated Chc ex-
pression facilitates the translocation of pStat3 from cytoplasm to
nuclear, which is essential for pStat3 to turn on its downstream target
genes. Both the increased Egfr recycling and nuclear localization of
pStat3 allow thyroid cells to gain proliferative advantages and hormone
independence, representing an initiation step of cellular transformation.
Increasing evidence suggests that aberrant cargo transported by
CMEmay lead to a constitutive activation of survival signals favoring tu-
morigenesis. At cell junctions, CME is also implicated in integrin inter-
nalization and an aberrant CME increases cell invasiveness [20]. So far,
Chc has been reported to have its expression changed only in hepatocel-
lular carcinoma [21,22]. Our expression proﬁling analysis of Chc on
MNG and PTC samples (with wild-type TITF1) showed that Chc is only
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the elevated expression of Chc and pSTAT3 by A339V TTF1 only repre-
sents an early event that contributes to the development of MNG.
Other effects triggered by the expression of the mutant TTF1 and/or
the second hit that occurred during perturbed cell growth are likely re-
quired for the development of PTC. Indeed, multiple genes and path-
ways were found to be affected by the A339V mutation. A339V TTF1
perturbed the expressions of the varied thyroid genes, including thyro-
tropin receptor (TSH-R) and thyroglobulin (TG), whichwork synergisti-
cally to mediate differentiation of thyroid cells [23]. The perturbation of
differentiation signals perhaps further prompted the aberrant growth ofthyroid cells. In addition, STAT3 activationwas associatedwith the cyto-
plasmic localization of p53, which has been suggested as a risk factor for
the development of neoplastic diseases [24]. A slight alternation of p53
pathway was also observed in our proteomic pathway data. This also
raised the possibility that perturbed p53 pathway could favor the accu-
mulation of somaticmutations in these rapidly dividing thyroid cells, fa-
voring disease progression. In particular, we found elevated pSTAT3
expression is highly correlated with CHC overexpression in MNG sam-
ples; it is conceivable that those factors or signals regulating STAT3 sig-
naling would be responsible for the sustainable growth of pre-
malignant thyroid cells and favor the PTC development. In other
Table 2
A comparison of characteristics between patients with benignmultinodular goiter (MNG)
and with papillary thyroid carcinoma (PTC).
MNG (n= 15) PTC (n= 13) p-valuea
Age of diagnosis in years,
median [range]
61.0 (30.0–90.0) 48.0 (8.0–82.0) 0.65
Sex (male/female) 1 / 14 4 / 9 0.09
History of thyroid surgery, no. [%] 1 [6.7] 1 [7.7] 1.000
History of thyrotoxicosis, no. [%] 1 [6.7] 0 [0.0] 1.000
Weight of excised thyroid
gland in grams, median [range]
21.0 [14.4–59.0] 21.0 [4.5–50.0] 0.519
Tumor size (cm) 3.0 (0.5–5.5) 1.5 (0.3–5.0) 0.065
Tumor multifocality – 7 [53.8] –
Tumor stage grouping
- T1 N0 M0 – 2 [15.4] –
- T1 N1b M0 – 1[7.7] –
- T2 N0 M0 – 1 [7.7] –
- T2 N1b M0 – 4 [30.8] –
- T4 N0 M0 – 1 [7.7] –
- T4 N1b M0 – 3 [23.1] –
- T4 N1b M1 – 1 [7.7] –
CHC overexpression, no.[%] 11 [73.3] 0 [0.0] b0.001
pSTAT3 overexpression, no.[%] 11 [73.3] 0 [0.0] b0.001
Abbreviation: CHC = clathrin heavy chain.
P values indicated in bold show the signiﬁcant difference between two groups.
a By Fisher-exact or Mann–Whitney U-tests.
1686 S.-T. Lau et al. / Biochimica et Biophysica Acta 1852 (2015) 1676–1686words, cumulative effects of all these perturbed pathways could con-
tribute to the pathogenesis of MNG and/or PTC.
In summary, our report here provides the ﬁrst evidence showing
that an up-regulated level of Chc promotes cellular transformation of
thyroid cells by enhancing CME-dependent Egfr recycling and transport
of pStat3. In addition, our ﬁndings offer a broader spectrum of points of
intervention and also provide relevant insights to the risk assessment or
prevention measure for MNG.
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doi.org/10.1016/j.bbadis.2015.05.005.
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